EQS-News: Darwin AG to Present at Invest 2026 in Stuttgart and the Equity Forum in Frankfurt
|
EQS-News: Darwin AG
/ Key word(s): Conference
Corporate News Darwin AG to Present at Invest 2026 in Stuttgart and the Equity Forum in Frankfurt Munich, April 9, 2026 – Darwin AG (ISIN DE000A3C35W0) will be participating in two capital markets conferences in spring 2026, namely the Invest conference in Stuttgart and the Equity Forum (German Spring Conference 2026) in Frankfurt. At both conferences, members of the management team will be giving a presentation on the company, its equity story, as well as recent developments, and will also be available for one-on-one meetings. Invest, the leading expo for finance and investment, will take place from April 17 to 18, 2026, at Messe Stuttgart. The conference is targeted at retail investors and covers a broad range of investment types and topics across the finance sector. Guided by the theme “Invest in the Future of Precision Health,” Dr. Daniel Wallerstorfer, CEO of Darwin AG, will present the Company’s equity story on April 17, 2026, at 5:30 p.m. and provide an exclusive insight into how personalized solutions are shaping tomorrow’s healthcare market. Interested visitors can meet the management of Darwin AG on-site in Hall 4, Booth 4E32, to learn about personalized health and the products of Darwin AG as well as its subsidiaries. Further information about Invest can be found here. The Equity Forum’s 2026 Spring Conference will take place from May 11 to 12, 2026, at the Flemings Selection Hotel in Frankfurt. It is a MiFID II-compliant professional event for institutional investors, financial analysts, as well as venture capital and private equity investors. Darwin AG will present a corporate update and audited financial results for 2025 to investors, analysts, and financial journalists, and will also provide an operational and strategic outlook. The 2025 consolidated financial statements will be published in the Annual Report on May 12, 2026. The presentation will take place on May 12, 2026, from 9:20 a.m. to 9:55 a.m. Following the presentation, Dr. Daniel Wallerstorfer, CEO of Darwin AG, will be available for one-on-one meetings. Individual meetings can be scheduled via the event tool on the conference website. More information about the 2026 German Spring Conference can be found here.
About Darwin AG The “Darwin Group” (i.e. Darwin AG including its subsidiaries), headquartered in Munich (Germany), is a European healthcare company, particularly active in the field of human genetics and the development of personalized products based on genetic analysis. The genetic analyses conducted in the company’s own laboratory are used in the diagnosis, treatment, and prevention of diseases, as well as in the production of individually tailored nutritional supplements and cosmetics. Darwin also acts as a partner to physicians, therapists, pharmacists, nutritionists, and fitness trainers, helping to ensure treatment or support that is as optimal as possible for the patient’s or client’s needs by analyzing their respective genetic predispositions. In addition, Darwin holds investments in innovative companies in the biotech, healthcare, and life sciences sectors. More information: https://darwin-biotech.com/
Contact
09.04.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
2305190 09.04.2026 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | ||
| Sales1 | 0,00 | 161,76 | 223,81 | 18,17 | 25,29 | 55,00 | 70,00 | |
| EBITDA1,2 | 0,00 | 30,16 | 72,82 | 1,61 | 35,79 | -3,50 | 2,70 | |
| EBITDA-Margin3 | 0,00 | 18,65 | 32,54 | 8,86 | 141,52 | -6,36 | 3,86 | |
| EBIT1,4 | 0,00 | 29,66 | 65,05 | -3,74 | 26,37 | -6,60 | 0,50 | |
| EBIT-Margin5 | 0,00 | 18,34 | 29,07 | -20,58 | 104,27 | -12,00 | 0,71 | |
| Net Profit (Loss)1 | 0,00 | 19,39 | 42,88 | 0,04 | 18,47 | 3,50 | 0,65 | |
| Net-Margin6 | 0,00 | 11,99 | 19,16 | 0,23 | 73,03 | 6,36 | 0,93 | |
| Cashflow1,7 | 0,00 | 10,39 | 95,15 | -18,95 | -24,89 | -6,00 | -1,50 | |
| Earnings per share8 | 0,00 | 1,62 | 3,76 | 0,01 | 1,54 | 0,29 | 0,05 | |
| Dividend per share8 | 0,00 | 0,44 | 1,75 | 0,56 | 0,56 | 0,56 | 0,56 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Treuhandgesellschaft Südbayern
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Darwin | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A3C35W | DE000A3C35W0 | AG | 109,80 Mio € | 02.11.2021 | Kaufen | 8FWH4HVG+4F |
| PE 2027e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 18,30 | 9,42 | 1,94 | 16,64 | 1,13 | -4,41 | 2,00 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,56 | 0,56 | 0,56 | 6,12% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 26.06.2026 | 15.10.2025 | 05.12.2025 | 12.05.2026 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +1,25% | +17,72% | +18,83% | +33,58% | +28,87% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
